Index · Artikel · Roche digs in for long fight for Illumina

Roche digs in for long fight for Illumina

2012-02-08 5
   
Advertisement
résuméZURICH Swiss drugmaker Roche is digging in for a long fight after gene sequencing company Illumina rejected its $5.7 billion hostile takeover bid as inadequate and said it would be more successful on its own. Roche, which offered to pay $44.50 per sh
Advertisement

Roche digs in for long fight for Illumina


ZURICH Swiss drugmaker Roche is digging in for a long fight after gene sequencing company Illumina rejected its $5.7 billion hostile takeover bid as inadequate and said it would be more successful on its own.

Roche, which offered to pay $44.50 per share when it launched the bid for Illumina last month, reiterated on Wednesday that it believed its offer was "full and fair" and that it was ready to start discussions with Illumina.

On Tuesday, Illumina - which has already adopted a "poison pill" defense strategy - told shareholders not to tender any of their shares to Roche, saying the offer failed to properly value its existing and coming products.

A deal would give Roche's diagnostics unit a leading position in the market for gene sequencing, which can help better identify which patients benefit from a given drug.

Although it faces a drawn-out battle for the San Diego-based group, analysts expect Roche, which has a history of success with such hostile takeouts, to prevail in the end.

"Next step for Roche could be to show the good intent, sugarcoat the deal and then start pitching the transaction to Illumina's major shareholders. Ultimately they hold the key to close the deal," Vontobel analyst Andrew Weiss said.

Roche initially offered $40 a share for Illumina, according to a filing with the U.S. Securities and Exchange Commission. That offer, subject to certain conditions, was made in a letter to Illumina on January 3, the filing said.

But when it announced its approach on January 25, it made an offer of $44.50.

Investors say Basel-based Roche may have to raise its bid to around $60 per share to win Illumina. Shares in Illumina, which also posted better-than-expected fourth-quarter earnings on Tuesday, closed on Tuesday at $51.80.

Roche raised offers in other bidding situations, even after it declared initial salvoes a full-and-fair value, such as for biotech company Genentech and test maker Ventana.

When chief executive Severin Schwan was diagnostics head, Roche in 2008 overcame months-long resistance from Ventana to snap it up for $3.4 billion. It had made an unsolicited, low-end bid, before increasing its original offer by 19 percent.

NO WHITE KNIGHT?

Some investors have said a rival bid is unlikely as few would be prepared to take on as determined a bidder as Roche.

"It's hard to see anybody else emerging as a bidder. The fit is best with Roche and I don't think any other competitor in that space would be willing to pay a higher price than Roche. Also you really need a diagnostics business to get the synergies," Sarasin analyst David Kaegi said.

But one person familiar with the deal said if the bidding process for Illumina does drag on, this would give other interested parties time to have a good look at the company.

Roche rivals Sanofi, Novartis and AstraZeneca have said they don't see a need to match Roche in buying a gene-decoding business, favoring partnerships instead.

Pharma industry bankers and analysts say Siemens, General Electric, Thermo Fisher Scientific, Danaher, Agilent Technologies and Johnson & Johnson are seen as potential interlopers.

Illumina is a major player in the emerging field of gene sequencing.

It makes machines that decode a person's entire genome, going far beyond simple genetic tests that are already used in diseases such as cancer to test for a handful of gene variations.

(Additional reporting by Caroline Copley in Zurich and Douwe Miedema in London; Editing by Erica Billingham and Jodie Ginsberg)

  • Roche digs in for long fight for Illumina

    Roche digs in for long fight for Illumina
    ZURICH Swiss drugmaker Roche is digging in for a long fight after gene sequencing company Illumina rejected its $5.7 billion hostile takeover bid as inadequate and said it would be more successful on its own. Roche, which offered to pay $44.50 per sh
    2012-02-08 ROCHEILLUMINA
  • Roche in $5.7 billion bid for gene decoder Illumina

    Roche in $5.7 billion bid for gene decoder Illumina
    ZURICH/LONDON Swiss drugmaker Roche Holding AG ROG.VX has offered $5.7 billion in cash in a hostile bid to take over Illumina Inc (ILMN.O), and investors are already betting that the U.S. gene sequencing company will command a significantly higher pr
    2012-01-25 ROCHEILLUMINA
  • Illumina board rejects sweetened Roche offer

    Illumina board rejects sweetened Roche offer
    n">Illumina Inc said on Monday that its board unanimously rejected Roche Holding's increased offer to buy the genetic sequencing company for $51 per share, or about $6.7 billion, saying it dramatically undervalued the company. Illumina management
    2012-04-03 ROCHEILLUMINA
  • Roche calls offer for Illumina "starting point"

    Roche calls offer for Illumina "starting point"
    n">Swiss drugmaker Roche Holding AG, in a letter to Illumina Inc shareholders, called its sweetened $51-a-share offer for the maker of genetic analysis equipment "a more than reasonable starting point for negotiations." The latest salvo
    2012-04-11 ROCHEILLUMINA
  • Roche Q1 sales solid as Illumina bid battle rages

    Roche Q1 sales solid as Illumina bid battle rages
    ZURICH Swiss drugmaker Roche said it would have to rethink its tactics if shareholders of reluctant U.S. bid target Illumina did not back its approach as it reported strong first-quarter pharmaceutical sales helped by top cancer drugs. Genetics speci
    2012-04-12 ROCHE
  • Roche, under fire, offers compromise in flu drug fight

    Roche, under fire, offers compromise in flu drug fight
    LONDON Roche has offered an olive branch to scientific critics in a bid to end a bitter fight over blockbuster flu drug Tamiflu that has led to calls for a boycott of the Swiss drugmaker's products. Tamiflu has been approved by regulators worldwide a
  • Roche in $550 million deal for superbug-fighting antibiotic

    Roche in $550 million deal for superbug-fighting antibiotic
    ZURICH Swiss drugmaker Roche will pay up to 500 million Swiss francs ($548 million) for an experimental antibiotic, marking a rare foray by a major pharmaceutical firm into the battle against so-called "superbug" infections found in hospitals. T
    2013-11-04 ROCHEPOLYPHOR
  • Roche team develops armed antibody in antibiotic fight

    Roche team develops armed antibody in antibiotic fight
    LONDON Researchers at Roche have developed a new weapon to fight hard-to-treat bacteria by arming an antibody with an antibiotic to reach and kill bugs hidden inside cells. The approach is similar to an existing technique used by scientists at the Sw
  • Roche sees more cancer success as sales top forecast

    Roche sees more cancer success as sales top forecast
    ZURICH Swiss drugmaker Roche Holding AG is banking on a new generation of breast cancer medicines to drive sales growth after strong demand for its established cancer treatments helped it to top forecasts in the third quarter. Most of Roche's best-se
    2012-10-16 ROCHE
  • Roche buys rights to Oryzon's cancer-suppressing gene drug

    Roche buys rights to Oryzon's cancer-suppressing gene drug
    ZURICH Roche has bought the rights to an experimental drug from Spain's Oryzon Genomics that can switch on genes to block cancer growth, as the Swiss drugmaker looks to maintain its dominance in the lucrative field of oncology. The world's largest ma
    2014-04-07 ROCHEORYZON
  • Sanofi launches $9.3 billion fight for U.S. cancer firm Medivation

    Sanofi launches $9.3 billion fight for U.S. cancer firm Medivation
    LONDON/PARIS French drugmaker Sanofi went public with a $9.3 billion offer to buy Medivation on Thursday, setting up what could be a lengthy takeover battle after the U.S. cancer firm rebuffed its approaches. The decision to target Medivation marks a
    2016-04-29 SANOFIMEDIVATION
  • Tamiflu resistance reported in 23 patients: Roche

    Tamiflu resistance reported in 23 patients: Roche
    CHICAGO Roche Holding AG said on Friday there have been just 23 reported cases in which H1N1 swine flu has resisted the effects of antiviral drug Tamiflu. Tamiflu, made by Roche and Gilead Sciences Inc, is one of two drugs shown to work well against
    2009-09-11 FLUROCHETAMIFLU
  • New review questions benefit of Roche drug Tamiflu

    New review questions benefit of Roche drug Tamiflu
    LONDON There is no clear evidence that Roche's widely used drug Tamiflu prevents complications such as pneumonia in people with flu, a group of medical experts said on Tuesday. Governments around the world have mobilized Tamiflu stockpiles to fight s
    2009-12-08 FLUTAMILFU
  • Experts find compound to fight bird, seasonal flu

    Experts find compound to fight bird, seasonal flu
    HONG KONG Scientists have identified a chemical compound that can stop the H5N1 bird flu virus as well as seasonal human flu viruses from replicating. Finding new flu drugs is essential as flu viruses mutate and are adept at evading the limited array
    2010-05-31 FLUCHEMICAL
  • FDA approval of Roche melanoma drug may come early

    FDA approval of Roche melanoma drug may come early
    LOS ANGELES U.S. regulators are moving quickly with Roche's application for targeted melanoma drug vemurafenib, which could receive approval as early as this week, according to a source familiar with the situation. A pivotal trial found that advanced
    2011-08-09 MELANOMAROCHE
  • Rivals see no need to match Roche's big gene bet

    Rivals see no need to match Roche's big gene bet
    DAVOS, Switzerland Roche Holding AG's rivals Sanofi SA and Novartis AG see no need to match the Swiss drug maker in buying a gene-decoding business like Illumina Inc and reckon they can do partnerships instead. The relaxed attitude in the face of Roc
    2012-01-27 ROCHEDAVOSRIVALS
  • Insight: Training immune system to fight cancer comes of age

    Insight: Training immune system to fight cancer comes of age
    NEW YORK More than 100 years after researchers first explored the potential to harness the body's immune system to fight cancer, the field's leading doctors see the concept finally proving itself on a large scale in the next year or two. Two drugs ba
    2012-05-07 IMMUNOTHERAPY
  • Roche Alzheimer's drug picked for major test

    Roche Alzheimer's drug picked for major test
    CHICAGO Roche Holding AG's Genentech unit has won the right to try its experimental Alzheimer's drug crenezumab on people with no signs of dementia - the first such trial to gauge whether early intervention can help prevent or slow the disease. The d
    2012-05-15 ALZHEIMERSGenentech
  • Roche banks on new drugs as Herceptin faces hurdle

    Roche banks on new drugs as Herceptin faces hurdle
    LONDON Swiss drugmaker Roche Holding AG expects results from 19 late-stage clinical trials over the next 18 months, providing a stream of products to offset a potential near-term threat to breast cancer drug Herceptin, its third biggest seller. The w
    2012-09-05 CANCERROCHERESEARCH
  • Long-serving Roche chairman to step down next year

    Long-serving Roche chairman to step down next year
    ZURICH Roche's influential Chairman Franz Humer said on Tuesday he will not stand for re-election next year when he will have served 16 years at the helm, potentially accelerating a shift of emphasis towards the Swiss drugmaker's U.S. operations. "Ro
    2013-03-05 ROCHECHAIRMAN

TOP

  • Day/
  • Week/
  • Original/
  • Recommand

Updated